Mengmeng Pan

Mengmeng Pan

Auto-generated profile, based on publicly available information

Mengmeng Pan

Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2015 in CrystEngComm
Verified
Journal Article
Closed access
PDF file
LHLei Han
Lei Han
YHYanhua Hu
Yanhua Hu
MPMengmeng Pan
Mengmeng Pan
YXYangfan Xie
Yangfan Xie
Yangyang LiuYangyang Liu
Yangyang Liu
XDXiangting Dong
Xiangting Dong
Y2O2S:Yb3+/Er3+ hollow nanofibers were synthesized via inheriting the morphology of electrospinning-derived precursors and exhibited excellent up-conversion luminescence properties.

9 June 2021 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
MPMengmeng Pan
Mengmeng Pan
PYPingping Yang
Pingping Yang
FWFangce Wang
Fangce Wang
XLXiu Luo
Xiu Luo
BLBing Li
Bing Li
ALAi-Bin Liang
Ai-Bin Liang
Background: With the improvement of clinical treatment outcomes in diffuse large B cell lymphoma (DLBCL), the high rate of relapse in DLBCL patients is still an established barrier, as the therapeutic strategy selection based on potential targets remains unsatisfactory. Therefore, there is an urgent need in further exploration of prognostic biomarkers so as to improve the prognosis of DLBCL.Methods: The univariable and multivariable Cox regression models were employed to screen out gene signatures for DLBCL overall survival (OS) prediction. The differential expression analysis was used to identify representative genes in high-risk and low-risk groups, respectively, where student t test and fold change were implemented. The functional difference between the high-risk and low-risk groups was identified by the gene set enrichment analysis.Results: We conducted a systematic data analysis to screen the candidate genes significantly associated with OS of DLBCL in three NCBI Gene Expression Omnibus (GEO) datasets. To construct a prognostic model, five genes (CEBPA, CYP27A1, LST1, MREG, and TARP) were then screened and tested using the multivariable Cox model and the stepwise regression method. Kaplan–Meier curve confirmed the good predictive performance of this five-gene Cox model. Thereafter, the prognostic model and the expression levels of the five genes were validated by means of an independent dataset. High expression levels of these five genes were significantly associated with favorable prognosis in DLBCL, both in training and validation datasets. Additionally, further analysis revealed the independent value and superiority of this prognostic model in risk prediction. Functional enrichment analysis revealed some vital pathways responsible for unfavorable outcome and potential therapeutic targets in DLBCL.Conclusion: We developed a five-gene Cox model for the clinical outcome prediction of DLBCL patients. Meanwhile, potential drug selection using this model can help clinicians to improve the clinical practice for the benefit of patients.

29 January 2026 in Blood
Verified
Journal Article
Closed access
MPMengmeng Pan
Mengmeng Pan
DWDi Wang
Di Wang
JXJie Xu
Jie Xu
SJShiwei Jin
Shiwei Jin
YWYan Wang
Yan Wang
JMJian-Qing Mi
Jian-Qing Mi
GPRC5D has emerged as a promising therapeutic target in relapsed/refractory multiple myeloma (R/R MM), particularly following progression after B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell (CAR-T) therapies. RD118 is a novel CAR-T therapy incorporating a fully human single-domain antibody fragment targeting GPRC5D. In this phase 1 study, 18 R/R patients (17 with MM and 1 with a history of primary plasma cell leukemia) received a single infusion of RD118 at 1.0 × 106, 2.0 × 106, or 3.0 × 106 CAR+ T cells per kg. At a median follow-up of 17.0 months, the overall response rate (ORR) was 94.4%, including 72.2% complete or stringent complete responses. Among the 7 patients previously exposed to BCMA-directed CAR-T therapy, ORR reached 85.7%. Median progression-free survival (PFS) was 18.2 months (95% confidence interval, 14.4 to not estimable), with 12-month PFS and overall survival rates of 82.1% and 93.3%, respectively. Cytokine release syndrome occurred in 88.9% of the patients, primarily grade 1 to 2. One patient developed grade 3 immune effector cell–associated neurotoxicity, which resolved within 72 hours. No cerebellar toxicities or treatment-related deaths were reported. These findings support that RD118 is a highly effective and safe therapeutic option for heavily pretreated R/R MM. This trial was registered at www.clinicaltrials.gov as #NCT05759793 and #NCT05219721.

21 July 2020 in Research Square
Verified
Preprint
Open access
PDF file
MPMengmeng Pan
Mengmeng Pan
PYPingping Yang
Pingping Yang
FWFangce Wang
Fangce Wang
XLXiu Luo
Xiu Luo
BLBing Li
Bing Li
ALAibin Liang
Aibin Liang
BACKGROUND With the improvement of clinical treatment outcomes in Diffuse large B cell lymphoma (DLBCL), the high rate of relapse in DLBCL patients is still an established barrier, due to the therapeutic strategy selection based on potential target remains unsatisfactory. Therefore, there is an urgent need in further exploration of prognostic biomarkers so as to improve the prognosis of DLBCL.METHODS The univariable and multivariable Cox regression models were employed to screen out gene signatures for DLBCL overall survival prediction. The differential expression analysis was used to identify representative genes in high-risk and low-risk groups, respectively, by student t test and fold change. The functional difference between the high-risk and low-risk groups were identified by the gene set enrichment analysis.RESULTS We conducted a systematic data analysis to screen the candidate genes significantly associated with overall survival of DLBCL in three NCBI Gene Expression Omnibus (GEO) datasets. To construct a prognostic model, five genes (CEBPA, CYP27A1, LST1, MREG, and TARP) were then screened and tested using the multivariable Cox model and the stepwise regression method. Kaplan-Meier curve confirmed the good predictive performance of the five-gene Cox model. Thereafter, the prognostic model and the expression levels of the five genes were validated by means of an independent dataset. All five genes were significantly favorable for the prognosis in DLBCL, both in training and validation datasets. Additionally, further analysis revealed the independence and superiority of the prognostic model in risk prediction. Functional enrichment analysis revealed some vital pathways resulting in unfavorable outcome and potential therapeutic targets in DLBCL.CONCLUSION We developed a five-gene Cox model for the clinical outcome prediction of DLBCL patients. Meanwhile, potential drug selection using this model can help clinicians to improve the clinical practice for the patients.